|
US20060106020A1
(en)
*
|
2004-04-28 |
2006-05-18 |
Rodgers James D |
Tetracyclic inhibitors of Janus kinases
|
|
JP2008508358A
(ja)
|
2004-08-02 |
2008-03-21 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
US7884109B2
(en)
|
2005-04-05 |
2011-02-08 |
Wyeth Llc |
Purine and imidazopyridine derivatives for immunosuppression
|
|
EP2354140A1
(en)
*
|
2005-05-20 |
2011-08-10 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
|
WO2007007919A2
(en)
|
2005-07-14 |
2007-01-18 |
Astellas Pharma Inc. |
Heterocyclic janus kinase 3 inhibitors
|
|
CA2621261C
(en)
|
2005-09-22 |
2014-05-20 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
US7989459B2
(en)
|
2006-02-17 |
2011-08-02 |
Pharmacopeia, Llc |
Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
|
|
US7919490B2
(en)
|
2006-10-04 |
2011-04-05 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
US7902187B2
(en)
|
2006-10-04 |
2011-03-08 |
Wyeth Llc |
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
TW200837064A
(en)
|
2006-10-04 |
2008-09-16 |
Pharmacopeia Inc |
8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
|
|
BRPI0622030A2
(pt)
*
|
2006-11-16 |
2014-04-22 |
Pharmacopeia Llc |
Derivados de purina 7-substituída, para imunossupressão
|
|
AU2007322033B2
(en)
|
2006-11-20 |
2013-07-11 |
President And Fellows Of Harvard College |
Methods, compositions, and kits for treating pain and pruritis
|
|
US8071779B2
(en)
|
2006-12-18 |
2011-12-06 |
Inspire Pharmaceuticals, Inc. |
Cytoskeletal active rho kinase inhibitor compounds, composition and use
|
|
US20100022517A1
(en)
*
|
2006-12-18 |
2010-01-28 |
Richards Lori A |
Ophthalmic formulation of rho kinase inhibitor compound
|
|
CA2673038C
(en)
*
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
|
EP2121681B1
(en)
|
2007-01-11 |
2015-04-15 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
|
AR064879A1
(es)
|
2007-01-12 |
2009-04-29 |
Astellas Pharma Inc |
Compuesto de piridina condensado
|
|
WO2008098096A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Anti-cytokine heterocyclic compounds
|
|
KR20150036210A
(ko)
|
2007-06-13 |
2015-04-07 |
인사이트 코포레이션 |
야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
|
|
CL2008001709A1
(es)
*
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
DE102007027800A1
(de)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
|
|
UA104849C2
(uk)
*
|
2007-11-16 |
2014-03-25 |
Інсайт Корпорейшн |
4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
|
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
|
HUE029767T2
(en)
*
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
WO2009155565A1
(en)
*
|
2008-06-20 |
2009-12-23 |
Genentech, Inc. |
Triazolopyridine jak inhibitor compounds and methods
|
|
CN102131389A
(zh)
*
|
2008-06-20 |
2011-07-20 |
健泰科生物技术公司 |
三唑并吡啶jak抑制剂化合物和方法
|
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
|
JP2011529918A
(ja)
*
|
2008-08-01 |
2011-12-15 |
バイオクライスト ファーマシューティカルズ， インコーポレイテッド |
Ｊａｋ３阻害剤としてのピペリジン誘導体
|
|
KR101335843B1
(ko)
|
2008-08-20 |
2013-12-02 |
조에티스 엘엘씨 |
피롤로[2,3-ｄ]피리미딘 화합물
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
TWI720517B
(zh)
|
2009-01-15 |
2021-03-01 |
美商英塞特公司 |
製造ｊａｋ抑制劑之方法及相關中間化合物
|
|
WO2010093808A1
(en)
|
2009-02-11 |
2010-08-19 |
Reaction Biology Corp. |
Selective kinase inhibitors
|
|
CA2758359A1
(en)
*
|
2009-04-14 |
2010-10-21 |
Astellas Pharma Inc. |
Fused pyrrolopyridine derivative
|
|
AR076794A1
(es)
|
2009-05-22 |
2011-07-06 |
Incyte Corp |
Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
|
|
SI2432472T1
(sl)
*
|
2009-05-22 |
2019-11-29 |
Incyte Holdings Corp |
3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
|
|
WO2011003418A1
(en)
|
2009-07-08 |
2011-01-13 |
Leo Pharma A/S |
Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
|
|
JP6205133B2
(ja)
|
2009-07-10 |
2017-09-27 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
|
|
TWI466885B
(zh)
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
|
IN2012DN01983A
(https=)
|
2009-08-24 |
2015-07-24 |
Ascepion Pharmaceuticals Inc |
|
|
TW201113285A
(en)
*
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
|
EA021478B1
(ru)
|
2009-10-09 |
2015-06-30 |
Инсайт Корпорейшн |
ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
|
|
ES2426407T3
(es)
*
|
2009-10-15 |
2013-10-23 |
Pfizer Inc. |
Compuestos de pirrolo[2,3-d]pirimidina
|
|
AU2010339444A1
(en)
|
2009-12-30 |
2012-07-19 |
Arqule, Inc. |
Substituted pyrrolo-aminopyrimidine compounds
|
|
JP5858434B2
(ja)
*
|
2010-02-18 |
2016-02-10 |
インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ |
Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
|
|
WO2011109217A2
(en)
*
|
2010-03-02 |
2011-09-09 |
Immunodiagnostics, Inc. |
Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors
|
|
EP3354652B1
(en)
|
2010-03-10 |
2020-05-06 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
|
EP2552915B1
(en)
|
2010-04-01 |
2017-07-19 |
Critical Outcome Technologies Inc. |
Compounds for the treatment of hiv
|
|
PE20130216A1
(es)
|
2010-05-21 |
2013-02-27 |
Incyte Corp |
Formulacion topica para un inhibidor de jak
|
|
WO2012054364A2
(en)
*
|
2010-10-22 |
2012-04-26 |
Merck Sharp & Dohme Corp. |
Bicyclic diamines as janus kinase inhibitors
|
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
|
US9233964B2
(en)
|
2011-01-07 |
2016-01-12 |
Leo Pharma A/S |
Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof
|
|
ES2547916T3
(es)
|
2011-02-18 |
2015-10-09 |
Novartis Pharma Ag |
Terapia de combinación de inhibidores de mTOR/JAK
|
|
RU2013144975A
(ru)
*
|
2011-04-08 |
2015-05-20 |
Пфайзер Инк. |
Кристаллические и некристаллические формы тофацитиниба и фармацевтическая композиция, содержащая тофацитиниб, и усилитель проникновения
|
|
CN103797010B
(zh)
|
2011-06-20 |
2016-02-24 |
因塞特控股公司 |
作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
|
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
ES3018133T3
(en)
|
2011-11-30 |
2025-05-14 |
Univ Emory |
Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
|
|
PT2796460T
(pt)
*
|
2011-12-21 |
2018-11-05 |
Shanghai hengrui pharmaceutical co ltd |
Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
TWI646099B
(zh)
|
2012-11-01 |
2019-01-01 |
英塞特控股公司 |
作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
|
|
PH12020551186B1
(en)
|
2012-11-15 |
2024-03-20 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
|
US10130632B2
(en)
|
2012-11-27 |
2018-11-20 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating renal disease
|
|
US9260426B2
(en)
*
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
|
CN103896946B
(zh)
*
|
2012-12-28 |
2018-04-03 |
浙江导明医药科技有限公司 |
用于预防及治疗多种自身免疫疾病的新化合物
|
|
WO2014113303A1
(en)
*
|
2013-01-16 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
4-fluoropiperidine orexin receptor antagonists
|
|
GEP201606600B
(en)
|
2013-02-22 |
2017-01-10 |
Pfizer |
Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
|
|
RS62867B1
(sr)
|
2013-03-06 |
2022-02-28 |
Incyte Holdings Corp |
Postupci i intermedijeri za dobijanje inhibitora jak
|
|
SMT202000315T1
(it)
|
2013-08-07 |
2020-07-08 |
Incyte Corp |
Forme di dosaggio a rilascio prolungato per un inibitore di jak1
|
|
WO2015027090A1
(en)
*
|
2013-08-22 |
2015-02-26 |
Genentech, Inc. |
Intermediates and processes for preparing compounds
|
|
CN105705499B
(zh)
*
|
2013-08-22 |
2018-10-12 |
基因泰克公司 |
用于制备化合物的方法
|
|
SI3077395T1
(en)
*
|
2013-12-05 |
2018-03-30 |
Pfizer Inc. |
Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
|
|
EP2924026A1
(en)
*
|
2014-03-28 |
2015-09-30 |
Novartis Tiergesundheit AG |
Aminosulfonylmethylcyclohexanes as JAK inhibitors
|
|
MA39987A
(fr)
|
2014-04-30 |
2017-03-08 |
Incyte Corp |
Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
WO2016024185A1
(en)
|
2014-08-12 |
2016-02-18 |
Pfizer Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
|
|
KR20180069782A
(ko)
|
2015-08-03 |
2018-06-25 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
하전 이온 채널 블록커 및 이용 방법
|
|
KR101771219B1
(ko)
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
|
US9630968B1
(en)
|
2015-12-23 |
2017-04-25 |
Arqule, Inc. |
Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
|
|
TW201811795A
(zh)
|
2016-08-24 |
2018-04-01 |
美商亞闊股份有限公司 |
胺基－吡咯并嘧啶酮化合物及其用途
|
|
EP3528816A4
(en)
*
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
|
WO2018134352A1
(en)
*
|
2017-01-20 |
2018-07-26 |
Leo Pharma A/S |
Bicyclic amines as novel jak kinase inhibitors
|
|
WO2018154133A1
(en)
*
|
2017-02-27 |
2018-08-30 |
Janssen Pharmaceutica Nv |
[1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
|
|
KR102821964B1
(ko)
|
2017-11-03 |
2025-06-19 |
어클라리스 쎄라퓨틱스, 인코포레이티드 |
치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
SG11202007164UA
(en)
|
2018-01-30 |
2020-08-28 |
Incyte Corp |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
|
KR102925957B1
(ko)
|
2018-02-16 |
2026-02-11 |
인사이트 코포레이션 |
사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
|
|
MA52655A
(fr)
|
2018-03-30 |
2021-02-17 |
Incyte Corp |
Biomarqueurs pour maladie cutanée inflammatoire
|
|
SMT202400306T1
(it)
|
2018-03-30 |
2024-09-16 |
Incyte Corp |
Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
|
|
CA3097025A1
(en)
|
2018-04-13 |
2019-10-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
CN119080779A
(zh)
|
2018-08-10 |
2024-12-06 |
阿克拉瑞斯治疗股份有限公司 |
吡咯并嘧啶itk抑制剂
|
|
CA3117969A1
(en)
|
2018-10-31 |
2020-05-07 |
Incyte Corporation |
Combination therapy for treatment of hematological diseases
|
|
WO2020132384A1
(en)
|
2018-12-21 |
2020-06-25 |
Celgene Corporation |
Thienopyridine inhibitors of ripk2
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
MX2021010869A
(es)
|
2019-03-11 |
2022-01-19 |
Nocion Therapeutics Inc |
Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
|
|
US10780083B1
(en)
|
2019-03-11 |
2020-09-22 |
Nocion Therapeutics, Inc. |
Charged ion channel blockers and methods for use
|
|
US10934263B2
(en)
|
2019-03-11 |
2021-03-02 |
Nocion Therapeutics, Inc. |
Charged ion channel blockers and methods for use
|
|
US10828287B2
(en)
|
2019-03-11 |
2020-11-10 |
Nocion Therapeutics, Inc. |
Charged ion channel blockers and methods for use
|
|
AU2020235888A1
(en)
|
2019-03-11 |
2021-09-30 |
Nocion Therapeutics, Inc. |
Charged ION channel blockers and methods for use
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
CA3138544A1
(en)
|
2019-05-02 |
2020-11-05 |
Aclaris Therapeutics, Inc. |
Substituted pyrrolopyridines as jak inhibitors
|
|
US20220235043A1
(en)
*
|
2019-07-31 |
2022-07-28 |
Aclaris Therapeutics, Inc. |
Substituted sulfonamide pyrrolopyridines as jak inhibitors
|
|
US20220372135A1
(en)
|
2019-09-27 |
2022-11-24 |
Disc Medicine, Inc. |
Methods for treating myelofibrosis and related conditions
|
|
WO2021072098A1
(en)
|
2019-10-10 |
2021-04-15 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
EP4041204A1
(en)
|
2019-10-10 |
2022-08-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
CN114828845A
(zh)
|
2019-11-06 |
2022-07-29 |
诺西恩医疗公司 |
带电的离子通道阻滞剂及其使用方法
|
|
US10933055B1
(en)
|
2019-11-06 |
2021-03-02 |
Nocion Therapeutics, Inc. |
Charged ion channel blockers and methods for use
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
JP7717065B2
(ja)
|
2019-11-22 |
2025-08-01 |
インサイト コーポレーション |
Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN119118953A
(zh)
|
2020-03-11 |
2024-12-13 |
诺西恩医疗公司 |
带电的离子通道阻滞剂及其使用方法
|
|
US12162851B2
(en)
|
2020-03-11 |
2024-12-10 |
Nocion Therapeutics, Inc. |
Charged ion channel blockers and methods for use
|
|
KR20230012539A
(ko)
|
2020-05-13 |
2023-01-26 |
디스크 메디슨, 인크. |
골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
PE20231743A1
(es)
|
2020-08-18 |
2023-10-31 |
Incyte Corp |
Proceso e intermediarios para preparar un inhibidor de jak
|
|
IL300557A
(en)
|
2020-08-18 |
2023-04-01 |
Incyte Corp |
Process and intermediates for preparing a JAK1 inhibitor
|
|
CA3191607A1
(en)
*
|
2020-09-08 |
2022-03-17 |
Gilles Ouvry |
Novel jak inhibitor compounds, method for synthesizing same and use thereof
|
|
WO2022054006A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Galderma Holding SA |
Novel jak inhibitor compounds, method for synthesizing same and use thereof
|
|
CA3204374A1
(en)
|
2020-12-08 |
2022-06-16 |
Incyte Corporation |
Jak1 pathway inhibitors for the treatment of vitiligo
|
|
WO2022194782A1
(en)
*
|
2021-03-15 |
2022-09-22 |
Chiesi Farmaceutici S.P.A. |
Heterocyclic derivatives as janus kinase inhibitors
|
|
UA129643C2
(uk)
|
2021-05-03 |
2025-06-18 |
Інсайт Корпорейшн |
Інгібітори шляху jak1 для лікування вузлуватого свербця
|
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
|
US12071439B2
(en)
|
2021-07-12 |
2024-08-27 |
Incyte Corporation |
Process and intermediates for preparing a JAK inhibitor
|
|
GEAP202416555A
(en)
|
2021-12-08 |
2024-10-28 |
Incyte Corp |
Anti-mutant calreticulin (calr) antibodies and uses thereof
|
|
KR20250136928A
(ko)
|
2023-03-06 |
2025-09-16 |
조에티스 서비시즈 엘엘씨 |
야누스 키나제 억제제를 함유하는 국소 조성물
|
|
WO2025096716A1
(en)
|
2023-11-01 |
2025-05-08 |
Incyte Corporation |
Anti-mutant calreticulin (calr) antibody-drug conjugates and uses thereof
|